SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-24-149141
Filing Date
2024-05-29
Accepted
2024-05-29 16:06:31
Documents
13
Period of Report
2024-04-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K/A d816859d8ka.htm   iXBRL 8-K/A 22211
  Complete submission text file 0001193125-24-149141.txt   149228

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA elvn-20240408.xsd EX-101.SCH 2887
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE elvn-20240408_lab.xml EX-101.LAB 18686
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elvn-20240408_pre.xml EX-101.PRE 11717
16 EXTRACTED XBRL INSTANCE DOCUMENT d816859d8ka_htm.xml XML 4360
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

IRS No.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39247 | Film No.: 24998357
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)